Clough Capital Partners L P Buys New Shares in TransMedics Group, Inc. $TMDX

Clough Capital Partners L P bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 7,119 shares of the company’s stock, valued at approximately $866,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Guggenheim Capital LLC grew its holdings in shares of TransMedics Group by 423.5% during the 4th quarter. Guggenheim Capital LLC now owns 12,542 shares of the company’s stock valued at $1,526,000 after purchasing an additional 10,146 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its position in TransMedics Group by 245.8% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 91,065 shares of the company’s stock valued at $11,078,000 after buying an additional 64,730 shares during the period. Cetera Investment Advisers boosted its position in TransMedics Group by 26.3% during the 4th quarter. Cetera Investment Advisers now owns 10,771 shares of the company’s stock valued at $1,310,000 after buying an additional 2,240 shares during the period. Stansberry Asset Management LLC purchased a new stake in TransMedics Group during the 4th quarter valued at $245,000. Finally, Trexquant Investment LP boosted its position in TransMedics Group by 15.0% during the 4th quarter. Trexquant Investment LP now owns 92,481 shares of the company’s stock valued at $11,250,000 after buying an additional 12,080 shares during the period. Institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of several analyst reports. Stifel Nicolaus dropped their price target on shares of TransMedics Group from $85.00 to $75.00 and set a “hold” rating for the company in a research report on Tuesday, May 26th. JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Piper Sandler dropped their price target on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen cut shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $134.00.

TransMedics Group Trading Down 3.4%

NASDAQ:TMDX opened at $73.22 on Thursday. The company has a 50-day moving average price of $84.57 and a 200-day moving average price of $113.51. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of 16.64 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. During the same period in the prior year, the business posted $0.70 earnings per share. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. Equities analysts predict that TransMedics Group, Inc. will post 1.98 EPS for the current year.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.